Physician profile
Hannah Meyer
NPI 1508484262
$818.94
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $369 · 2023: $139 · 2024: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $321.25 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $109.36 | 2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $64.11 | 2021 | |
| Tempus Ai, INC | $47.89 | 2024 | |
| Corium, LLC | $45.46 | 2022-2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $39.95 | 2022-2023 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $38.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.27 | 2022 | |
| Neurelis, INC. | $21.56 | 2022 | |
| Novo Nordisk INC | $15.46 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $14.91 | 2022 | |
| Organon LLC | $12.85 | 2024 | |
| Lilly USA, LLC | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.